Carcell Biopharma

Carcell Biopharma ("Carcell") is a global biotech company launched by EVX Ventures. With an innovative “hub-and-spoke” business model, Carcell accelerates innovations in and translation of next-generation cell and gene therapies. Carcell has two lead technology platforms. The first technological platform creates engineered red blood cells (eRBC) for allogeneic cell therapy against autoimmune diseases and cancer. The second technological platform is a lipid nanoparticle (LNP) platform that has a proprietary library and high throughput screening capabilities for effective nucleic acid delivery.